Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben. - PowerPoint PPT Presentation


PPT – Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben. PowerPoint presentation | free to view - id: 272a02-ZDc1Z


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben.


... International ... MAJOR THREATS TO PUBLIC HEALTH. 2. Potentially new and re-emerging ... and access to information. Brokering research into policy. ... – PowerPoint PPT presentation

Number of Views:186
Avg rating:3.0/5.0
Slides: 43
Provided by: cma143


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben.

ZUSAMMENARBEIT Gesundheit und Forschung
zugunsten kleiner und mittlerer Unternehmen
(KMUs) im 7. EU-Rahmenprogramm Ylva
Huber Bereich Europäische und Internationale
Programme FFG Österreichische
  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

(No Transcript)
Instrumente im 7. RP
7. EU-Rahmenprogramm 6. EU-Rahmenprogramm
Verbundprojekte (Collaborative Projects) Integrierte Projekte (IP) Gezielte Forschungsprojekte (STREPs)
Exzellenznetze (NoE) Exzellenznetze (NoE)
Koordinierungsmaßnahmen (CA) Koordinierungsmaßnahmen (CA)
Unterstützungsmaßnahmen (SSA) Unterstützungsmaßnahmen (SSA)
Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie) Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)
Einzelprojekte im ERC (Programm Ideas)
KMU spezifische Maßnahmen KMU spezifische Maßnahmen
Artikel 169 Artikel 169
Gemeinsame Technologieinitiativen (JTI)
Die Ausschreibungen sind geöffnet!
  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

  • Ziele
  • Verbesserung der Gesundheit der europäischen
  • Stärkung der europ. Industrie/Firmen im Bereich
  • Blick auf globale Gesundheitsfragen
  • (z.B. Epidemien
  • Schwerpunkte
  • Translationale Forschung (Grundlagenforschung ?
  • Neue Therapien (Entwicklung und Validierung)
  • Methoden zur Gesundheitsförderung,
  • Diagnostische Instrumente und medizinische
  • Effiziente Gesundheitssysteme

Thema 1- Gesundheit (6.050 Mio. Euro)
Thema 1 Gesundheit (6.050 Mio. )
Einreichfrist 1. Ausschreibung 19. April
2007 Einreichfrist 2. Ausschreibung 18.
September 2007

  • High-throughput research
  • Unifying human and model organism genetic
    variation databases
  • Temporal and spatial proteomics to study
    biological processes relevant to human health
  • Groundbreaking techniques for DNA sequencing and
  • 2. Call
  • SME-driven collaborative research projects for
    developing tools and technologies for
    high-throughput research
  • Detection, Diagnosis and Monitoring
  • Development of a hybrid imaging system
  • Novel optical methodologies for detection,
    diagnosis and monitoring of disease or
    disease-related processes
  • Novel targeted imaging probes for early in vivo
    diagnosis and/or evaluation of response to
  • In vivo image-guidance for cell therapy
  • 2. Call
  • Standardisation and improvement of pre-analytical
    procedures for in vitro diagnostics
  • High throughput molecular diagnostics in
    individual patients for genetic diseases with
    heterogeneous clinical presentation

  • Predicting suitability, safety and efficacy of
  • Thema zum Großteil durch Innovative Medicines
    Initiative (IMI) abgedeckt!
  • Novel alternative testing strategies for use in
    pharmaceutical discovery and development
  • Bottlenecks in reduction, refinement and
    replacement of animal testing in pharmaceutical
    discovery and development
  • Promotion, development, validation, acceptance
    and implementation of QSARs (quantitative
    structure-activity relationship) for toxicology
  • Alternative testing strategies for the assessment
    of the toxicological profile of nanoparticles
    used in medical diagnostics
  • In silico modelling for ADMET outcomes

  • Innovative therapeutic approaches and
  • Development and production of new generation
  • Innovative approaches for the development of
    vaccines for young children
  • Immunotherapy of human food allergies
  • 2.Call
  • Development of emerging gene therapy tools and
    technologies for clinical application
  • Stem cell lines for cell-based therapies.
  • Development of stem cell culture conditions.
  • Stem cells for kidney regeneration.
  • Adding value to EU stem cell therapy research
    scientific communication and future perspectives.

  • Large-scale data gathering
  • Networking biobanking initiatives across Europe
    developing standards and norms for existing and
    future human sample biobanks
  • Molecular epidemiological studies in existing
    well characterised European (and/or other)
    population cohorts
  • Comparative studies of genetic variation in
    humans towards a reference population in Europe
  • Characterisation and variability of the microbial
    communities in the Human Body
  • Structure-function analysis of membrane-transporte
    rs and channels for the identification of
    potential drug target sites
  • High throughput analysis of lipids and
    lipid-protein interactions
  • Genome-wide association studies in mammalian
    non-rodent models for the identification of genes
    relevant to human health and disease

  • Systems biology
  • A system approach to eukaryotic unicellular
    organism biology
  • Modelling of T-cell activation
  • Fundamental approaches to stem cell
  • Developing an integrated in vitro, in vivo and
    systems biology modelling approach to
    understanding apoptosis in the context of health
    and disease
  • 2. call
  • Multidisciplinary fundamental genomics and
    molecular biology approaches to study basic
    biological processes relevant to health and
  • Coordination and Support Actions in large-scale
    data gathering and systems biology
  • Traditional Chinese Medicine in post-genomic era.
    Specific International Cooperation Action.
    Targeted region China.

  • Brain and related diseases
  • Stroke and mechanisms underlying ischemic brain
  • Coding in neuronal assemblies
  • Neurobiology of anxiety disorders
  • Memory loss underlying mechanisms and therapy
  • From basic spinal mechanisms to spinal cord
    disease and trauma.
  • Neuron-glia interactions in health and disease
  • 2. Call
  • Restorative approaches for therapy of
    neurodegenerative diseases.
  • From mood disorders to experimental models.
  • Neuronal mechanisms of vision and related
  • Childhood and adolescent mental disorders.
    Specific International Cooperation Action. Target
    regions Eastern Europe and Central Asia and
    Western Balkans.

  • Human Development and Ageing
  • Novel approaches to reconstitute normal immune
    function at old age.
  • Termination of developmental processes and their
    reactivation in adult life
  • Biomarkers of ageing.
  • Increasing the participation of elderly in
    clinical trials.
  • Research on human development and/or healthy
    ageing across the EU

  • Anti-microbial drug resistance including fungal
  • 2. Call
  • Novel targets for drugs against Gram negative
  • Host-pathogen interactions in infections by
    Streptococcus pneumoniae.
  • An integrated platform for development and
    clinical evaluation of point-of-care diagnostic
    devices for microbial detection, antibiotic
    susceptibility determination and biomarkers
  • Molecular epidemiology to control nosocomial and
    community spreading of highly virulent multi-drug
    resistant strains of bacterial pathogens.
  • Health and economic cost of antimicrobial
  • Conference on genetic and biochemical tools for
    postgenomic physiological analysis of
    Staphylococcus, in particular MRSA.

  • HIV, AIDS, malaria and tuberculosis
  • HIV/AIDS Drug Discovery and Preclinical
  • Highly innovative approaches for research into
    host-pathogen interaction in tuberculosis
  • Development of fast tests for the diagnosis of
    Multi-Drug-Resistant strains of HIV, malaria and
    tuberculosis and of latent tuberculosis infection
  • Addressing knowledge gaps in pregnancy malaria.
  • New HIV Vaccines inducing broadly-reactive
    neutralising antibodies.
  • 2. Call
  • Network on HIV and anti-HIV drug resistance
  • HIV and Hepatitis co-infection
  • Blocking the transmission of malaria the
    mosquito vector target.
  • European network for study and clinical
    management of TB drug resistance.
  • Support platform for the development of PRD
  • Highly innovative research in HIV/AIDS, malaria
    and tuberculosis between Indian and European
    partners. (SICA, Targeted Region India)
  • Coordination of European research activities with
    global initiatives, including Public-Private-Partn
    erships (SICA Targeted Regions ICPC).
  • Next generation of researchers for HIV/AIDS,
    malaria, tuberculosis and neglected infectious
    diseases (SICA Targeted Regions ICPC).

  • Potentially new and re-emerging epidemics
  • Development of broadly protective influenza
    vaccine candidates.
  • Identifying immunological mechanisms of
    protection for influenza vaccines
  • Standardisation of immunological assays including
    surrogate markers for evaluation of new influenza
    vaccines in clinical trials
  • Innovative point-of-care diagnostic tests for
  • Development of additional treatment strategies
    for patients suffering from highly pathogenic
  • Development of pandemic influenza containment and
    mitigation strategies.
  • Supporting highly innovative inter-disciplinary
    research on influenza.
  • Influenza research in collaboration with Asian
    partners. (SICA, Targeted regions Asia)
  • 2. Call
  • Strengthening research on prediction,
    identification, modelling and surveillance of
    newly emerging infectious diseases in humans.
  • Definition of research needs and priorities in
    Europe in the area of Emerging Infectious

  • Cancer
  • Translating the knowledge on non-coding RNAs
    linked to the aetiology of cancer into novel
    diagnosis and therapy strategies.
  • Translating clinical omics-technology
    (genomics, proteomics, metabolomics) into
    innovative cancer biomarkers aiding in early
    diagnosis, prognosis and treatment selection of
    cancer patients.
  • Genomic instability and genomic alterations in
    pre-cancerous lesions and/or cancer.
  • Novel cancer screening methods.
  • Optimising research on end of life care of cancer
  • Understanding and fighting metastasis.
  • Improving targeted drug delivery to cancer cells
    for cancer therapeutics other than gene therapy
  • Developing high-throughput bioassays and models
    for human cancers in lower species.
  • 2. Call
  • Innovative combination clinical trials for
    multimodal cancer therapy.
  • Role of inflammation in tumour initiation and
  • Epidemiology of gene-environment interactions
    involved in carcinogenesis.
  • Translating the hypoxic tumour microenvironment.
  • ERA-NET on optimisation of the use of cancer
    registries for cancer research purposes
  • Studying cancer aetiology in Latin America. (SICA)

  • Cardiovascular Disease
  • Molecular basis of the inflammatory response and
    associated vascular remodelling in
  • Vascular remodelling in aneurysmal disease.
  • Combating stroke.
  • 2. Call
  • Congenital pathologies affecting the heart.
  • Cell therapies for the treatment of heart
  • Organ imaging in CVD.
  • Integrating pharmacogenomic approaches into the
    treatment of CVD.

  • Diabetes and Obesity
  • Early processes in the pathogenesis of type 1
    diabetes and strategies for early prevention.
  • Combined forms of diabetes in children.
  • Insulin resistance as a key factor in the
    development of diabetes and metabolic syndrome.
  • Pathophysiological mechanisms related to excess
  • A road-map for diabetes research.
  • 2. Call
  • Nutritional signals and the development of new
    diabetes/obesity therapeutic agents.
  • Markers and treatment for diabetic neuropathy
  • Geno- and phenotypical differentiation of type 2
    subjects and monogenic subjects.
  • Use of beta cell imaging in diabetes mellitus.

  • Rare Diseases
  • Natural course and pathophysiology of rare
  • Research capacity-building in the field of rare
  • Other Chronic Diseases
  • Osteoarthritis.
  • Inflammatory bowel disease.
  • Osteoporosis signalling pathways in bone
    formation and homeostasis.
  • Genetic factors of Osteoporosis.
  • Intervertebral disc degeneration prevention and
  • Innovative concepts in chronic obstructive
    pulmonary disease pathogenesis (COPD).
  • Hearing impairment and degeneration.
  • Impairment of touch and proprioception at old
  • Visual impairment and degeneration.
  • 2. Call
  • Understanding and combating age-related muscle
  • Translational research aiming for a treatment of
    urinary incontinence.

  • Translating clinical research into clinical
    practice including better use of
  • medicines, and appropriate use of behavioural and
  • interventions and health therapies and
  • 2.call
  • Implementation of research into healthcare
  • Self-medication and patient safety
  • Patient Safety Research Network
  • Improving clinical decision making
  • Better use of medicines.
  • Continuity of clinical care.
  • Patient self-management of chronic disease.
  • Quality, solidarity and sustainability of health

  • Enhanced health promotion and disease prevention
  • 2.call
  • Promoting healthy behaviour in children and
  • Interventions addressing the gradient of health
  • Public health interventions addressing the abuse
    of alcohol.
  • Evaluation of suicide prevention strategies
    across and within European countries.
  • Improve vaccination coverage
  • Horizontal Coordination and Support Actions
    across Optimising the Delivery
  • of Health Care to European Citizens
  • 2.call
  • Disease networks of centres of reference.

  • Specific International Cooperation Actions for
    Health System Research
  • 2.call
  • Epidemiological investigations into long-term
    trends of population health as consequence of
    socio-economic transitions, including life-style
    induced health problems. SICA (Mediterranean
    Partner countries, Russia, Eastern European and
    Central Asia)
  • Universal and equitable access to health care and
    health financing. SICA (MCP, ACP, Asia and Latin
  • Health care intervention research optimising
    hospital care. SICA (Western Balkans.)
  • Health care intervention research improving
    pre-natal and maternal care. SICA (ACP and
    Mediterranean Partner Countries)

  • Coordination and Support Actions across the Theme
  • Reinforcing the network of National Contact
    Points (NCP) for the Seventh Framework Programme
    under Health Theme by promoting transnational
  • Promoting participation of high-technology
    research intensive SMEs, operating in the
    biomedical engineering and other medical
    technology sectorsrelevant to Health Theme.
  • Assessment and valorisation of project outcome
    for hightechnology and research intensive SME
    participating to Framework Programmes of Research
    in the healthcare sector.
  • Science communication actions.
  • Initiatives to foster dialogue and debate on
    health research issues of interest to the public.
  • Studies on the impact of EU legislation on health
    research and related developments and
  • 2.call
  • Promotion and facilitation of international
    cooperation in areas relevant to the objectives
    of this theme. (SICA, ICPC)
  • Responding to EU policy needs (2.call)
  • Paediatric medicinal products, Drug safety
    research, Living and work conditions, Health
    statistics, Tobacco Control

Technologieplattformen und Gemeinsame
  • Mobilisierung europäischer Ressourcen im Bereich
    Forschung, technologische Entwicklung und
    Innovation durch Zusammenbringen aller Akteure
    eines definierten Forschungsbereiches (Industrie,
    KMU, Universitäten, Endverbraucher)
  • Industriegetrieben
  • Gemeinsame Definition und Erstellung einer
    strategischen Forschungsagenda (mittel- bis
  • Input zur Entwicklung der thematischen
    Programme im 7. RP
  • Einige wenige werden als Gemeinsame
    Technologieinitiativen (Joint Technology
    Initiatives) etabliert
  • Neuer Weg zur Realisierung von public-private
    partnerships auf EU-Ebene mit definierter
    rechtlicher Struktur

Example Innovative Medicines - en route to a
Joint Technology Initiative
  • Accelerated Development of safe and more
    effective medicines
  • Revitalization of the the biopharmaceutical
    research and development (RD) environment for
    Europe to become more competitive
  • Improving the collaboration between all relevant
    actors from public and private organisations
    (public-private partnerships)
  • Draft and Implementation of a European Research
  • Second version of the Strategic Research
    Agenda published recently
  • First Calls expected for end of 2007/beginning
    of 2008
  • http//europa.eu.int/comm/research/fp6/index_en.cf
  • http//rp7.ffg.at/RP7.aspx_param_target_is_116120.

  •  Innovative Medicines 
  • 2. version of the  Strategic Research Agenda 
  • 4 main topics
  • Safety
  • Early safety evaluation and risk
    assessment, creation of a European Centre
    for Drug Safety
  • Efficacy
  • Predictive pharmacology, biomarker
    identification and validation, patient
    recruitment and risk assessment
  • Knowledge Management
  • New technologies to control and analyse
    enormous quantities of information in an
    integrative and predictive way
  • Education and Training
  • Bridge gaps in expertise required to
    strengthen the biopharmaceutical RD process,
    creation of a European Medicines Research Academy

  • Technologieplattform
  •  Innovative Medicines 
  • Contact in Austria
  • Univ. Prof. Dr. Hans Georg Eichler,
  • Vice Rector of the Medical University in
  • vr_forschung_at_meduniwien.ac.at

Relevante Themen der 1. Ausschreibungen aus
anderen Bereichen
  • Food, Agriculture, Fisheries and Biotechnology
  • e.g. Fork to farm Food (including seafood),
    health and well being
  • Information and Communication Technologies
  • Objective ICT-2007.5.3 Virtual Physiological
  • Nanosciences, Nanotechnologies, Materials and new
  • Technologies
  • Creation of a critical and commented database on
    the health,
  • safety and environmental impact of nanoparticles
  • Substantial innovation in the European medical
    industry development of
  • nanotechnology-based systems for in-vivo
    diagnosis and therapy (in
  • Coordination with topic HEALTH-2007-2.4.1-7 and
    HEALTH-2007-1.2-3 in
  • Theme 1 "Health")
  • Environment Environment and Health
  • Security Topic SEC-2007-1.3-05 Water
    distribution surveillance Critical
  • Protection

  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

Zusammenarbeit zwischen Industrie und
  • Forschung zugunsten von Kleinen und Mittleren
    Unternehmen (KMUs)
  • Forschung zugunsten von KMU-Verbänden

  • Themen Bottom up Ansatz (gesamtes Feld der
    Wissenschaft Technologie)
  • KMUs/KMU-Verbände lagern Forschung
    technologische Entwicklung aus
  • Flexibilität bezüglich der intellectual property

  • Forschungs- und technologische Entwicklungsaktivit
  • Demonstrationsaktivitäten
  • Andere Aktivitäten (Trainings, dissemination
  • Management-Aktivitäten

Research for SMEs
Project participation scheme
at least 3 SMEs from at least 3 countries (MS,
at least 2 universities research
centres industrial companies research performing
Research for SME-Associations
Project participation scheme
at least 2 universities research
centres industrial companies research performing
at least 3 SME-Ass. from at least 3 countries
(MS, AS) or 1 European SME-Ass. at least 2 SMEs
Research for SMEs/ SME-Associations
Research for SMEs Research for SME associations
Duration 1 - 2 years 2 - 3 years
Number of partners 5 - 10 10 -15
Total budget 0.5 1.5 Million 1.5 4 Million
Activities RD, demonstration, management, other activities RD, demonstration, management, other activities
Share of RD carried out by RTD performers
60 Source European Commission
  • Research for SMEs FP7-SME-2007-1
  • Einreichfrist
    4.September 200
  • Research for SME Associations

  • Einreichfrist 1. Juni 2007
  • Kontakt Dr. Ines Haberl, ines.haberl_at_ffg.at
  • http//rp7.ffg.at/RP7.aspx
  • http//cordis.europa.eu/en/home.html

Wichtige Dokumente zur Vorbereitung
  • Arbeitsprogramme Annexes
  • Guide for Applicants
  • Rules for Participation
  • Model Grant Agreement
  • Leitfaden/Formular für Anbahnungsfinanzierung
  • rp7.ffg.at -gt Services der FFG

Kontaktieren Sie uns! Ihre Ansprechpartner für
Life Sciences in der FFG/ Bereich Europäische und
Internationale Programme
  • Mag. Birgit Steininger
  • Leiterin des Referats für Biowissenschaften,
  • Nationale Kontaktstelle für Lebensmittel,
    Landwirtschaft und Biotechnologie (DW 4101)
  • birgit.steininger_at_ffg.at
  • Dr. Ylva Huber
  • Nationale Kontaktstelle für Gesundheit (DW 4102)
  • ylva.huber_at_ffg.at
  • Dr. Ines Haberl
  • Nationale Kontaktstelle für KMUs (DW 4103)
  • Ines.haberl_at_ffg.at
  • e-mail vorname.nachname_at_ffg
    .at, Tel 43/57755-Durchwahl

Vielen Dank für Ihre Aufmerksamkeit viel
Erfolg für Ihre Projekte im 7. Rahmenprogramm!
About PowerShow.com